Researchers have introduced the concept that the cost of extending life with a defibrillator in young and otherwise healthy subjects with genetic cardiac disorders can be balanced by society gains when the lifespan of an individual is considered. Through computer-based analytical models, the study, published in Annals of Noninvasive Electrocardiology, shows that primary intervention with defibrillator therapy is cost-effective and even cost-gaining in this population.
Defibrillator therapy, the implantation of a defibrillator in patients with high-risk genetic cardiac disorders, but without a history of prior aborted cardiac arrest, used in early intervention can reduce the risk of sudden cardiac death and significantly prolong life, say researchers.
“The implanted cardioverter defibrillator has been shown to efficiently terminate life-threatening arrhythmias affecting patients born with genetic abnormalities in the electrical system of the heart,” states Dr. Ilan Goldenberg of the Heart Research Follow-Up Program at the University of Rochester Medical Center. “However, data on the yield of this mode of therapy derives mostly from studies of adult patients with acquired cardiac disease. In the present study, we employ an analytical model based on current knowledge of the risks of patients with genetic cardiac disorders and show that in this high-risk population, intervention with a defibrillator at the age of 10 years is cost effective or even associated with economic gains due to the societal contributions of young and otherwise healthy patients in whom defibrillator therapy extends life.”
Sharon Agsalda | alfa
World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern
Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern
21.07.2017 | Event News
19.07.2017 | Event News
12.07.2017 | Event News
21.07.2017 | Earth Sciences
21.07.2017 | Power and Electrical Engineering
21.07.2017 | Physics and Astronomy